$ELDN
Eledon Pharmaceuticals, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022011698 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.203M $13.13M $3.320M
YoY Change -3.52% 30.67% 242.27%
% of Gross Profit
Research & Development $6.182M $23.74M $3.040M
YoY Change 103.36% 287.13% 128.57%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $9.385M $23.74M $6.360M
YoY Change 47.56% 287.13% 176.52%
Operating Profit -$36.87M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $7.000K $40.00K
YoY Change -100.0% -91.14% 100.0%
Pretax Income -$9.385M -$36.86M -$6.310M
YoY Change 48.73% 58.78% 52.42%
Income Tax -$579.0K -$2.354M -$400.0K
% Of Pretax Income
Net Earnings -$8.806M -$34.50M -$5.900M
YoY Change 49.25% 51.24% 42.51%
Net Earnings / Revenue
Basic Earnings Per Share -$2.33
Diluted Earnings Per Share -$594.4K -$2.328M -$2.115M
COMMON SHARES
Basic Shares Outstanding 14.82M 1.431M
Diluted Shares Outstanding 14.82M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.83M $84.83M $114.2M
YoY Change -25.72% -25.72% 1197.73%
Cash & Equivalents $84.83M $84.83M $114.2M
Short-Term Investments
Other Short-Term Assets $34.00K $3.513M $38.00K
YoY Change -10.53% 170.23% -29.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $88.35M $88.35M $115.6M
YoY Change -23.6% -23.58% 1059.66%
LONG-TERM ASSETS
Property, Plant & Equipment $768.0K $768.0K $100.0K
YoY Change 668.0% 668.0% 1900.0%
Goodwill $48.65M $48.65M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $400.0K $383.0K
YoY Change 4.44% 0.0% -40.06%
Total Long-Term Assets $82.20M $82.20M $81.56M
YoY Change 0.79% 0.74% 8395.31%
TOTAL ASSETS
Total Short-Term Assets $88.35M $88.35M $115.6M
Total Long-Term Assets $82.20M $82.20M $81.56M
Total Assets $170.5M $170.5M $197.2M
YoY Change -13.51% -13.52% 1703.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.813M $1.813M $1.366M
YoY Change 32.72% 29.5% 315.2%
Accrued Expenses $2.588M $2.588M $1.100M
YoY Change 135.27% 135.27% 10.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.401M $4.401M $2.483M
YoY Change 77.25% 76.04% 87.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $400.0K $400.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $400.0K $400.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.401M $4.401M $2.483M
Total Long-Term Liabilities $400.0K $400.0K $0.00
Total Liabilities $6.553M $6.553M $6.589M
YoY Change -0.55% -0.71% 349.45%
SHAREHOLDERS EQUITY
Retained Earnings -$114.9M -$80.39M
YoY Change 42.92% 39.61%
Common Stock $278.9M $271.0M
YoY Change 2.92% 304.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $164.0M $164.0M $190.6M
YoY Change
Total Liabilities & Shareholders Equity $170.5M $170.5M $197.2M
YoY Change -13.51% -13.52% 1703.91%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$8.806M -$34.50M -$5.900M
YoY Change 49.25% 51.24% 42.51%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$9.208M -$28.90M -$9.430M
YoY Change -2.35% 89.98% 364.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -449.0K 9.160M
YoY Change -100.0% -100.41%
NET CHANGE
Cash From Operating Activities -9.208M -28.90M -9.430M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 -449.0K 9.160M
Net Change In Cash -9.208M -29.36M -270.0K
YoY Change 3310.37% -127.86% -86.7%
FREE CASH FLOW
Cash From Operating Activities -$9.208M -$28.90M -$9.430M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.74
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05555555555
CY2021 eldn Period For Which Cumulative Change In Ownership Annual Use Net Operating Loss And Research And Development Credit Carryforwards
PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards
P3Y
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05555555555
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.05
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.01
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.10
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.87
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.01
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.03
CY2021Q4 us-gaap Liabilities
Liabilities
6553000
CY2020Q4 us-gaap Liabilities
Liabilities
6589000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14306788
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4106000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
400000
CY2021 dei Auditor Firm
AuditorFirmId
170
CY2021 dei Auditor Name
AuditorName
KMJ Corbin & Company LLP
CY2021 dei Auditor Location
AuditorLocation
Irvine, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84833000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114195000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3513000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1435000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
88346000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
115630000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
768000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
138000
CY2021Q4 us-gaap Goodwill
Goodwill
48648000
CY2020Q4 us-gaap Goodwill
Goodwill
48648000
CY2021Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2020Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
400000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
383000
CY2021Q4 us-gaap Assets
Assets
170548000
CY2020Q4 us-gaap Assets
Assets
197185000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1813000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1366000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
144000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2219000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
973000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4401000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2483000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14306788
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15160397
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15160397
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
278880000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
270974000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114899000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80393000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
163995000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
190596000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170548000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
197185000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23735000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6131000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13132000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3171000
CY2021 eldn Deferred Tax Liability
DeferredTaxLiability
2354000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10052000
CY2020 us-gaap Restructuring Charges
RestructuringCharges
2282000
CY2020 eldn Warrant Inducement Expense
WarrantInducementExpense
4829000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36860000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23215000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2354000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-404000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22811000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14819582
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
190596000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7904000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
163995000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
9465000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8550000
CY2020 eldn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5380000
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1194000
CY2020 eldn Cancellation Of Common Stock In Connection With Reverse Split Value
CancellationOfCommonStockInConnectionWithReverseSplitValue
-25000
CY2020 eldn Temporary Equity Stock Issued During Period Value Acquisitions
TemporaryEquityStockIssuedDuringPeriodValueAcquisitions
69723000
CY2020 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
95226000
CY2020 eldn Adjustments To Additional Paid In Capital Fair Value Of Options Assumed In Acquisition
AdjustmentsToAdditionalPaidInCapitalFairValueOfOptionsAssumedInAcquisition
2950000
CY2020 eldn Adjustments To Additional Paid In Capital Fair Value Of Warrants Assumed In Acquisition
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAssumedInAcquisition
12944000
CY2020 eldn Warrants Issued During Period Inducement Expense
WarrantsIssuedDuringPeriodInducementExpense
4829000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3171000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22811000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
190596000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22811000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
CY2021 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
195000
CY2020 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
178000
CY2020 eldn Warrant Inducement Expense
WarrantInducementExpense
4829000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7904000
CY2020 eldn Deferred Tax Liability
DeferredTaxLiability
404000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2095000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2143000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-39000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-200000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-180000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28913000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15212000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
11035000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11035000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
95226000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5380000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
450000
CY2020 eldn Cash Paid For Cancellation Of Common Stock In Connection With Reverse Split
CashPaidForCancellationOfCommonStockInConnectionWithReverseSplit
25000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-449000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109581000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29362000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
105404000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114195000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8791000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84833000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114195000
CY2021 eldn Increase In Operating Lease Asset And Liability Due To Lease
IncreaseInOperatingLeaseAssetAndLiabilityDueToLease
825000
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1000
CY2020 eldn Conversion Of Series X1 Non Voting Convertible Preferred Stock Into Common Stock
ConversionOfSeriesX1NonVotingConvertiblePreferredStockIntoCommonStock
13000
CY2020 eldn Issuance Of Common Stock In Acquisition
IssuanceOfCommonStockInAcquisition
1194000
CY2020 eldn Issuance Of Series X Non Voting Convertible Preferred Stock In Acquisition
IssuanceOfSeriesXNonVotingConvertiblePreferredStockInAcquisition
69723000
CY2020 eldn Fair Value Of Options Assumed In Acquisition
FairValueOfOptionsAssumedInAcquisition
2950000
CY2020 eldn Fair Value Of Warrants Assumed In Acquisition
FairValueOfWarrantsAssumedInAcquisition
12944000
CY2020 eldn Accrued Offering Costs
AccruedOfferingCosts
450000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34500000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28900000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84800000
CY2021Q4 eldn Working Capital
WorkingCapital
83900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114900000
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-eighteen
CY2021 eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-22811000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.33
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.72
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14819582
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1451432
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1087174
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
632543
CY2021 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
CY2021Q4 eldn Income Tax Examination Likelihood Of Favorable Settlement
IncomeTaxExaminationLikelihoodOfFavorableSettlement
0.50
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1344000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1157000
CY2021Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2039000
CY2020Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
89000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
96000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
41000
CY2020Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
110000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
34000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
38000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3513000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1435000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1411000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
98000
CY2021Q4 eldn Accrued Severance Current
AccruedSeveranceCurrent
104000
CY2020Q4 eldn Accrued Severance Current
AccruedSeveranceCurrent
12000
CY2021Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
454000
CY2020Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
258000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
167000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9000
CY2020Q4 eldn Accrued Financing Costs
AccruedFinancingCosts
450000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
83000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2219000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
973000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
387000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
212000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
200000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
799000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
30000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
769000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
400000
CY2019Q4 us-gaap Goodwill Gross
GoodwillGross
0
CY2020Q4 us-gaap Goodwill Gross
GoodwillGross
48648000
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2021Q4 us-gaap Goodwill Gross
GoodwillGross
48648000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
283000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
195000
CY2021Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2020Q4 eldn Contingent Liability
ContingentLiability
0
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
208000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
188000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
825000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M28D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0300
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0325
CY2021Q4 eldn Contingent Liability
ContingentLiability
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37055000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23408000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
195000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
193000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36860000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23215000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2746000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-404000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
392000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2354000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-404000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2354000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-404000
CY2021 eldn Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2020 eldn Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7741000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4875000
CY2021 eldn State Income Taxes Net Of Federal Tax Benefits
StateIncomeTaxesNetOfFederalTaxBenefits
-445000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
651000
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
215000
CY2020 eldn Effective Income Tax Rate Reconciliation Change In Warrant Fair Market Value Amount
EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount
1014000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
651000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
252000
CY2021 eldn Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
2000
CY2020 eldn Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
627000
CY2020 eldn Effective Income Tax Rate Reconciliation Section Three Hundred And Eighty Two Limitation On Net Operating Losses And Credits
EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits
10562000
CY2021 eldn Income Tax Reconciliation State Tax Rate Differential
IncomeTaxReconciliationStateTaxRateDifferential
235000
CY2021 eldn Nol True Up
NOLTrueUp
-991000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
146000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
89000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6440000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-7858000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2354000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-404000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12531000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5151000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1356000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
705000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
296000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
14000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1867000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
802000
CY2021Q4 eldn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1713000
CY2020Q4 eldn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1905000
CY2021Q4 eldn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
171000
CY2020Q4 eldn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
30000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17934000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8607000
CY2021Q4 eldn Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
171000
CY2020Q4 eldn Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
29000
CY2021Q4 eldn Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
7192000
CY2020Q4 eldn Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
6801000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7363000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6830000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12323000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5883000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1752000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4106000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
764000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
548000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
712000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
233000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
531000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
7000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
548000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1469000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
764000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6400000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6400000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5100000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 eldn Warrant Inducement Expense
WarrantInducementExpense
4800000
CY2021 eldn Number Of Stock Compensation Plans
NumberOfStockCompensationPlans
3
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-eighteen
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
91403
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
139.96
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2191462
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.15
CY2020 eldn Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
1346398
CY2020 eldn Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice
7.58
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7784
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
586.16
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3621479
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.63
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
702836
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.69
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
174
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.73
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
110164
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.50
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213977
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.33
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4132506
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.18
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1871327
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.64
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020 eldn Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
20088000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7904000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3171000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15900000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2021 us-gaap Restructuring Charges
RestructuringCharges
2300000
CY2020 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
120000
CY2020 eldn Business Acquisitions Pro Forma Research And Development Expense
BusinessAcquisitionsProFormaResearchAndDevelopmentExpense
9489000
CY2020 eldn Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
8317000
CY2020 eldn Business Acquisitions Pro Forma Restructuring Expense
BusinessAcquisitionsProFormaRestructuringExpense
2282000
CY2020 eldn Business Acquisition Pro Forma Operating Income Loss
BusinessAcquisitionProFormaOperatingIncomeLoss
-19968000
CY2020 eldn Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
79000
CY2020 eldn Business Acquisition Pro Forma Warrant Inducement Expense
BusinessAcquisitionProFormaWarrantInducementExpense
4829000
CY2020 eldn Business Acquisition Pro Forma Income Loss Before Provision For Income Taxes
BusinessAcquisitionProFormaIncomeLossBeforeProvisionForIncomeTaxes
-24718000
CY2020 eldn Business Acquisition Pro Forma Income Tax Expense Benefit
BusinessAcquisitionProFormaIncomeTaxExpenseBenefit
-404000
CY2020 eldn Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-24314000
CY2020 eldn Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-15.44
CY2020 eldn Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
1574657

Files In Submission

Name View Source Status
0001564590-22-011698-index-headers.html Edgar Link pending
0001564590-22-011698-index.html Edgar Link pending
0001564590-22-011698.txt Edgar Link pending
0001564590-22-011698-xbrl.zip Edgar Link pending
eldn-10k_20211231.htm Edgar Link pending
eldn-10k_20211231_htm.xml Edgar Link completed
eldn-20211231.xsd Edgar Link pending
eldn-20211231_cal.xml Edgar Link unprocessable
eldn-20211231_def.xml Edgar Link unprocessable
eldn-20211231_lab.xml Edgar Link unprocessable
eldn-20211231_pre.xml Edgar Link unprocessable
eldn-ex1012_1073.htm Edgar Link pending
eldn-ex1013_1071.htm Edgar Link pending
eldn-ex1014_1072.htm Edgar Link pending
eldn-ex231_12.htm Edgar Link pending
eldn-ex311_7.htm Edgar Link pending
eldn-ex312_15.htm Edgar Link pending
eldn-ex321_14.htm Edgar Link pending
eldn-ex322_16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcpkzcyxarqe000001.jpg Edgar Link pending
gcpkzcyxarqe000002.jpg Edgar Link pending
gcpkzcyxarqe000003.jpg Edgar Link pending
gcpkzcyxarqe000004.jpg Edgar Link pending
gcpkzcyxarqe000005.jpg Edgar Link pending
gk4rhrzuipsh000001.jpg Edgar Link pending
gxepvee453wv000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending